Non Hodgkin's Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Non-Hodgkin's Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-10-09
Oct 9, 2021
N
Recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
  • +1 more
2021-10-09
Oct 9, 2021
G
Terminated
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia
  • hLL1-DOX (IMMU-115)
  • Newark, Delaware
  • +5 more
2021-10-06
Oct 6, 2021
U
Active, not recruiting
  • Hodgkin's Lymphoma
  • +8 more
  • Reduced intensity haplodentical stem cell transplant
  • Myeloablative haploidentical stem cell transplant
  • Birmingham, United Kingdom
  • +11 more
2021-09-27
Sep 27, 2021
A
Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Phoenix, Arizona
  • +30 more
2021-09-23
Sep 23, 2021
S
Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Plasma Cell Myeloma
  • Hematopoietic Cell Transplantation
  • +2 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
2021-09-21
Sep 21, 2021
M
Active, not recruiting
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • +3 more
  • MB-CART20.1
  • Cologne, Germany
  • +1 more
2021-09-20
Sep 20, 2021
H
Completed
  • Non-Hodgkin's Lymphoma
  • +7 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-09-14
Sep 14, 2021
U
Active, not recruiting
  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • Miami, Florida
    University of Miami
2021-09-09
Sep 9, 2021
N
Recruiting
  • Follicular Lymphoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-09-04
Sep 4, 2021
N
Recruiting
  • Leukemia
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2021-09-02
    Sep 2, 2021
    N
    Completed
    • Chronic Myelogenous Leukemia
    • +9 more
    • Atlanta, Georgia
      Northside Hospital
    2021-08-30
    Aug 30, 2021
    T
    Completed
    • Non-Hodgkin's Lymphoma
    • +3 more
    • Sarasota, Florida
    • +6 more
    2021-08-20
    Aug 20, 2021
    G
    Terminated
    • Non-hodgkin's Lymphoma
    • +5 more
    • Newark, Delaware
    • +4 more
    2021-08-12
    Aug 12, 2021
    G
    Completed
    • Non-Hodgkin's Lymphoma
    • Lymphoma, B-Cell
    • radiolabeled epratuzumab
    • (no location specified)
    2021-08-12
    Aug 12, 2021
    G
    Completed
    • Non-Hodgkin's Lymphoma
    • +2 more
    • Lille, Cedex, France
    • +2 more
    2021-08-12
    Aug 12, 2021
    G
    Completed
    • Non-Hodgkin's Lymphoma
    • hA20-humanized anti-CD20 antibody
    • New York, New York
    • +2 more
    2021-08-12
    Aug 12, 2021
    B
    Active, not recruiting
    • Acute Lymphoblastic Leukemia
    • +3 more
    • Allodepleted T Cells
    • Houston, Texas
    • +1 more
    2021-08-13
    Aug 13, 2021
    C
    Recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    2021-08-09
    Aug 9, 2021
    E
    Active, not recruiting
    • Advanced Cancer
    • +5 more
    • Los Angeles, California
    • +7 more
    2021-08-05
    Aug 5, 2021